4543.T

$2127.00

Market ClosedAs of Mar 18, 6:19 AM UTC

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2127.00
Potential Downside
17.9%
Whystock Fair Value$1746.76
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. It operates through three segments: Cardiac and Vascular Company, Medical Care Solutions C...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.14T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.05
Beta
Defensive asset. Lower volatility than the S&P 500.
0.25
Div Yield
Strong income play. Yield provides a meaningful total return floor.
143.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
8.74%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.84

Recent News

Simply Wall St.
Feb 17, 2026

Terumo Record Q3 Highlights OrganOx Integration And Margin Story For Investors

Terumo (TSE:4543) reported record-high revenue and profit for its third quarter. North American demand and contributions from the recently acquired OrganOx business supported the result. The quarter also featured improved profit margins alongside the new revenue high. Terumo, a major medical technology group, is seeing its latest quarter shaped by hospital and procedure volumes, reimbursement trends, and ongoing demand for devices that support cardiovascular and surgical care. The record Q3...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Feb 17, 2026

Terumo Corp (TRUMF) Q3 2026 Earnings Call Highlights: Record Revenue and Strategic Acquisitions ...

Despite challenges from tariffs and foreign exchange, Terumo Corp (TRUMF) achieves record-high revenue and operating profit, driven by strong North American demand and strategic acquisitions.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MedTech Dive
Nov 24, 2025

Okami raises $45M to commercialize vascular embolization devices

The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Nov 15, 2025

Terumo (TSE:4543): Evaluating Value After Prolonged Share Price Decline

Terumo (TSE:4543) has recently caught the attention of investors following a sustained share price decline over the past month, with the stock down nearly 5% and extending to a 14% drop over the past 3 months. This pullback provides an interesting vantage point for those tracking trends in the healthcare sector. See our latest analysis for Terumo. Terumo’s recent pullback continues a broader downward trend, with the share price returning -20.87% year-to-date and the 1-year total shareholder...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Nov 13, 2025

US Shutdown End, FX, Earnings Nudge Asian Markets Higher

Asian stock markets were mixed on the high-side Thursday, as the US government shutdown ended, the y

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.